Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Income (2016 - 2025)

Ligand Pharmaceuticals' Non Operating Income history spans 16 years, with the latest figure at -$75.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 77.44% year-over-year to -$75.1 million; the TTM value through Dec 2025 reached -$89000.0, down 100.35%, while the annual FY2025 figure was -$89000.0, 100.35% down from the prior year.
  • Non Operating Income for Q4 2025 was -$75.1 million at Ligand Pharmaceuticals, down from $76.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $110.5 million in Q1 2024 and bottomed at -$75.1 million in Q4 2025.
  • The 5-year median for Non Operating Income is -$224000.0 (2021), against an average of $2.5 million.
  • The largest annual shift saw Non Operating Income tumbled 2924.38% in 2022 before it skyrocketed 515500.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$19.8 million in 2021, then soared by 178.0% to $15.5 million in 2022, then surged by 32.38% to $20.5 million in 2023, then tumbled by 306.94% to -$42.3 million in 2024, then crashed by 77.44% to -$75.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Non Operating Income are -$75.1 million (Q4 2025), $76.1 million (Q3 2025), and $1.4 million (Q2 2025).